Steve is a seasoned commercial executive with 25 years of experience building and leading high performing sales and marketing teams. Steve was most recently the Vice President, Commercial Development at Haematologic Technologies, a leading provider of products and analytical services to support the research, development, and commercialization of large molecule biotherapeutics. Prior to Haematologic Technologies, he held executive and senior level sales and marketing roles at several medical device firms including Bionique Testing labs, Rheonix Inc, Roche Tissue Diagnostic (formerly Ventana Medical Systems, Inc.), and Abbott Laboratories.
Steve holds a BS. Psychology from Arizona State University, and is a certified Medical Technologist, (MT, ASCP).
Steve joins Ultivue after a successful year of funding and looks to help strengthen its position as a market leader affording flexible options for multiplex immunofluorescence assays for digital pathology.
“This is a very exciting time to join the Ultivue team and accelerate the adoption of our technology by scientists seeking to illuminate the biology behind cancer and other diseases, and work with drug developers to help speed the progress of life saving therapeutics into the clinic. I’m thrilled to lead this team of deeply committed and talented individuals as we seek to broaden the commercialization of this ground-breaking technology”, said Pemberton.
“Ultivue’s rapid growth and product expansion is driven by our corporate culture and the inspiring team dynamics. We’re very pleased to have Steve join the team. His style and experience perfectly compliment our recipe for success” noted Jacques Corriveau, President and CEO.
About Ultivue
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and a scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. For more information, visit ultivue.com.
Ultivue
Adrian Arechiga Ph.D.
VP Marketing
+49 176 3039 0757
Adrian.arechiga@Ultivue.com
Mark Rees Ph.D.
VP Corporate and Business Development
+1 5165124977
Mark.Rees@ultivue.wpenginepowered.com
Fenel Eloi is a highly seasoned life sciences executive experienced in leading the transformation of small and mid-size companies to large operating global organizations. Mr. Eloi served as the CFO and then COO at Cell Signaling Technology, a bio-reagents company, from 2005 to 2018, where he provided leadership in the transformation of the company to a global operation. He currently serves on the Board of Directors and chairs the audit committee of 908 Devices, Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis. He also serves on the board of directors of MitoTherapeutix, a privately held drug development biotech company. “I am very excited to join Ultivue and help them scale their operations to the next level. This is an exciting time for spatial biology and Ultivue has a great opportunity to rapidly grow and favorably impact both their customers’ search for improved cancer treatments and patients’ lives,” said Mr. Eloi.
Mary Pat Lancelotta is currently Vice President, Corporate Marketing and Communications at Adaptive Biotechnologies (Nasdaq: ADPT), a pioneer and leader in immune medicine. She is a seasoned healthcare strategist with a passion for precision medicine and brings over 20 years of business and strategy experience. Prior to Adaptive, Mary Pat led corporate and Product Marketing for Foundation Medicine, a molecular information company. Before joining Foundation Medicine, she led corporate strategic initiatives and strategic planning at Quest Diagnostics. Mary Pat holds an MBA with honors from Columbia Business School and a BS in Biochemistry from Boston College. She is also on the board of directors of Molecular Match, a clinical decision support company, and the TargetCancer Foundation. “I am delighted to join the Board of Ultivue and look forward to working with the management team and fellow Board members to help grow the business, especially in the area of artificial intelligence to support image analysis,” said Mary Pat Lancelotta. “As we look to the future, working with big pharma, CRO and academic medical center customers, Ultivue has a tremendous opportunity to expand the impact of spatial biology on patients’ lives.”
“It’s an exciting time at Ultivue,” noted Jacques Corriveau, President and CEO. “The combination of Mary Pat’s ability to drive innovative commercial strategy for a global market alongside Fenel’s experience enabling technology advancements within our partnership ecosystem will help our customers bring exciting new therapies to market and positively impact the drive toward personalized cancer treatment.”
hafadmin Categories: News Tags: Announcement Comments 953 Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision MedicineUltivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically-relevant markers combined with same slide-H&E analysis in precious tissue samples.
Fluidigm is a leader in high-parameter imaging for the clinical translational research and clinical testing markets. It’s Imaging Mass Cytometry™ (IMC™) technology is designed for highly multiplexed targeted interrogation of tissue sections for 40 or more protein markers in one scan, with distinct non-overlapping signals from element-labeled antibodies detected simultaneously for each sub-micrometer pixel.
The collaboration provides reseachers with end-to-end service capability for clinical and translational work. For example, InSituPlex technology is well suited to identify regions of interest that may require downstream, deep profiling with IMC™. Customer access to both technologies can improve the efficiency of drug discovery programs and, in translational research, enable patient stratification to triage cases that require further investigation.
“Imaging Mass Cytometry has become integral to the clinical translational research and clinical testing markets,” said Chris Linthwaite, Fluidigm President and CEO. “Through Fluidigm Therapeutic Insights Services, we will offer our customers access to our technology as well as that of Ultivue, providing optimum imaging solutions for biomarker discovery and drug development.”
“Ultivue is at the forefront of innovation to provide unique biological insights for our customers,” said Mark Rees, Vice-President of Business Development at Ultivue. “Our InSituPlex® technology offers valuable profiling of the tissue and expands the depth of information possible from a single section that is complementary to the high-parameter capabilities of Imaging Mass Cytometry. We believe this joint offering with Fluidigm will now provide researchers a seamless workflow enabling a far more efficient biomarker discovery and drug development process.”
About Fluidigm
Fluidigm Corporation (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all.
Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. For Research Use Only. Not for use in diagnostic procedures. For more information, visit fluidigm.com.
About Ultivue
Ultivue, Inc. provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. For more information, visit ultivue.com.
Ultivue
Mark Rees, PhD
Vice President Corporate Development
(+1) 516-512-4977
mark.rees@ultivue.wpenginepowered.com
Fluidigm
Mark Spearman
Senior Director, Corporate Communications
(+1) 650-243-6621
mark.spearman@fluidigm.com
CAMBRIDGE, MA – Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping, today announced the completion of a $50 million Series D round of financing. New investors include Ally Bridge Group, Pura Vida Investments and Tao Capital Partners. Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC.
This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows.
Anna Yaeger, President and Portfolio Manager commented, “Ally Bridge Group is excited to be long term partners with Ultivue. We believe the company’s differentiated kit-based approach to multiplex immunofluorescence is well positioned to capitalize on the spatial biology revolution and creates maximum flexibility to support academic, biopharma, and CRO customers.”
“What Ultivue has is remarkably capable. They provide fast, accurate, previously unattainable multiplexed protein marker information at high resolution and on existing hardware. It is going to be exciting to see a well-resourced, well led Ultivue offer great capabilities to the biotech and pharma oncology community,” said Keith Crandell, Co-founder & Managing Director from ARCH Ventures.
“Ultivue is driving to make immunotherapy a reality for every patient that needs it with leading technology that enables advanced exploration and interrogation of tissue samples for precision medicine research. We’re proud to continue supporting the Ultivue team,” said Adam Wieschhaus, Ph.D., CFA, Director at Northpond Ventures.
“We’re excited to welcome our newest investors, and greatly appreciate the support from our existing investment partners,” says Jacques Corriveau, President and CEO of Ultivue. “This funding will allow us to expand our commercial efforts while also increasing the scope of our research and development in order to remain at the forefront of innovation and provide biological insights for our customers as they work to address the challenge of therapeutic response rates in patients using immunotherapy.”
hafadmin Categories: News Tags: Announcement Comments 949 Ultivue announces new executive team memberRichard is a seasoned financial professional with more than thirty years of experience in finance, accounting, internal audit, financial planning, and treasury roles. Richard was most recently the Vice President & Controller at Oxford Immunotec Global PLC a global diagnostic company, where he was responsible for the worldwide accounting, finance, and treasury functions during their initial public offering, three acquisitions, a divestiture and sale of the company. Prior to Oxford Immunotec, he held Controller and other senior financial roles at several medical device and high technology firms including Salient Surgical Technologies, Neurometrix, and Teradyne.
Richard holds an MS from the MIT Sloan School of Management and a BA in economics from Trinity College.
Richard joins Ultivue as the company completes its Series D round of funding and looks to strengthen its position as a market leader in multiplex immunofluorescence assays for digital pathology.
” This is a very exciting time to join the Ultivue team as we continue to accelerate our growth to support our customers as they solve complex therapeutic challenges.”
“Richard carries with him the epitome of professionalism and experience,” notes Jacques Corriveau, President and CEO at Ultivue. “These are crucial traits to have in a financial partner as Ultivue looks toward its future as a mainstay in the market.”
hafadmin Categories: News Tags: Announcement Comments
News
950
Ultivue announces new executive team member
